Skip to content
Agentic OS
Menu

Intelligence / B2B SaaS / Acquisitions / Theriva Biologics, Inc.

M&Acompleted an acquisition (SEC 8-K)2 Nov 2026

Theriva Biologics, Inc.

2 Nov 2026: Completed an acquisition (SEC 8-K) · Pharma and biotech. Recorded in the SEC EDGAR full-text search.

View the source record

Filed
2 Nov 2026
Ticker
TOVX
Role
Completed an acquisition
Sector
Pharma and biotech
Sic
2834
Items
1.01, 2.01, 7.01, 9.01
Summary
The Closing occurred on October 30, 2026. Regulation FD Disclosure. On November 2, 2026, the Company issued a press release announcing the Agreement, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Location
Rockville, MD
State
Maryland
Country
United States
SEC CIK
894158
Reference
0001104659-26-121318
What this signal means

Integration means consolidating tools and vendors: the buyer re-platforms the target, and an acquired company's stack is reviewed by its new owner.

  1. Completed an acquisition leads with 189 of 292, then Sold assets or a business (82).
  2. 103 added in the 30 days to 19 Nov 2026.
Reach them with AOS

Find the decision makers at Theriva Biologics, Inc.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this m&a signal, for your approval.

Start free

More in Completed an acquisition

Acquisitions

See all

Source: SEC EDGAR full-text search, data to 19 Nov 2026. Every Form 8-K reporting Item 2.01 (completion of an acquisition or disposition of assets) filed with the SEC in the last 90 days. The role (buyer, company acquired, seller) is read from the filing's own wording, which is quoted on each row. AOS shows what the public record says; it does not verify or endorse the company.